Trial Profile

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 986115 (Primary)
Indications Fibroma
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms RINGSIDE
Sponsors Ayala Pharmaceuticals; Immunome

Most Recent Events

13 Jan 2025 According to an Immunome media release, Immunome expects to report topline data in the second half of 2025.
13 Nov 2024 According to an Immunome media release, full enrollment for the Phase 3 RINGSIDE Part B study of AL102 for the treatment of desmoid tumors was completed in February 2024.
26 Sep 2024 Planned End Date changed from 25 Feb 2025 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com